Invesco Ltd. Has $8.40 Million Stake in Artivion, Inc. $AORT

Invesco Ltd. raised its holdings in Artivion, Inc. (NYSE:AORT) by 27.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 341,656 shares of the company’s stock after acquiring an additional 74,589 shares during the period. Invesco Ltd. owned about 0.80% of Artivion worth $8,398,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in Artivion by 25.1% in the fourth quarter. Millennium Management LLC now owns 165,482 shares of the company’s stock valued at $4,731,000 after acquiring an additional 33,220 shares during the period. Illinois Municipal Retirement Fund grew its stake in Artivion by 3.1% in the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company’s stock valued at $504,000 after acquiring an additional 611 shares during the period. Principal Financial Group Inc. grew its stake in Artivion by 2.4% in the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company’s stock valued at $5,083,000 after acquiring an additional 4,749 shares during the period. Deutsche Bank AG grew its stake in Artivion by 45.1% in the fourth quarter. Deutsche Bank AG now owns 36,982 shares of the company’s stock valued at $1,057,000 after acquiring an additional 11,501 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Artivion by 3.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company’s stock valued at $645,000 after acquiring an additional 727 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Marshall S. Stanton sold 26,132 shares of the firm’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $28.44, for a total value of $743,194.08. Following the completion of the sale, the senior vice president directly owned 79,200 shares of the company’s stock, valued at $2,252,448. This trade represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company’s stock, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 87,790 shares of company stock valued at $3,190,959. 8.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. LADENBURG THALM/SH SH cut Artivion from a “buy” rating to a “neutral” rating and boosted their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. JMP Securities increased their price objective on Artivion from $33.00 to $42.00 and gave the stock a “market outperform” rating in a report on Friday, August 8th. Wall Street Zen upgraded Artivion from a “hold” rating to a “buy” rating in a report on Monday. Needham & Company LLC increased their price objective on Artivion from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday. Finally, Stifel Nicolaus increased their price objective on Artivion from $36.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Artivion has an average rating of “Buy” and a consensus price target of $40.63.

Artivion Stock Performance

Shares of NYSE AORT opened at $43.53 on Tuesday. The stock has a 50 day moving average price of $33.95 and a 200 day moving average price of $28.92. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $45.07. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The stock has a market capitalization of $2.05 billion, a PE ratio of -103.64 and a beta of 1.64.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.